300966 Stock Overview
Engages in the research, development, production, and sale of steroid drug raw materials and intermediates in China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Hubei Goto Biopharm Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥14.93 |
| 52 Week High | CN¥28.78 |
| 52 Week Low | CN¥12.03 |
| Beta | 0.0067 |
| 11 Month Change | -2.29% |
| 3 Month Change | -30.10% |
| 1 Year Change | -24.56% |
| 33 Year Change | -66.80% |
| 5 Year Change | n/a |
| Change since IPO | -73.80% |
Recent News & Updates
Hubei Goto Biopharm Co.,Ltd. (SZSE:300966) Held Back By Insufficient Growth Even After Shares Climb 26%
May 12
Hubei Goto BiopharmLtd's (SZSE:300966) Soft Earnings Are Actually Better Than They Appear
May 02Recent updates
Shareholder Returns
| 300966 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -11.6% | -6.6% | -2.3% |
| 1Y | -24.6% | -21.7% | -17.3% |
Return vs Industry: 300966 underperformed the CN Biotechs industry which returned -22.2% over the past year.
Return vs Market: 300966 underperformed the CN Market which returned -18.4% over the past year.
Price Volatility
| 300966 volatility | |
|---|---|
| 300966 Average Weekly Movement | 6.3% |
| Biotechs Industry Average Movement | 5.8% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in CN Market | 8.9% |
| 10% least volatile stocks in CN Market | 3.7% |
Stable Share Price: 300966's share price has been volatile over the past 3 months.
Volatility Over Time: 300966's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 631 | Zubin Xi | www.gotobiopharm.com |
Hubei Goto Biopharm Co.,Ltd. engages in the research, development, production, and sale of steroid drug raw materials and intermediates in China and internationally. It offers starting materials, such as androstenedione, bisnordiol, and 9-hydroxyandrostenedione; intermediates, including sex hormone, progesterone, corticosteroid, and other pharmaceutical raw materials.
Hubei Goto Biopharm Co.,Ltd. Fundamentals Summary
| 300966 fundamental statistics | |
|---|---|
| Market cap | CN¥1.72b |
| Earnings (TTM) | CN¥22.53m |
| Revenue (TTM) | CN¥569.20m |
76.4x
P/E Ratio3.0x
P/S RatioIs 300966 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300966 income statement (TTM) | |
|---|---|
| Revenue | CN¥569.20m |
| Cost of Revenue | CN¥450.78m |
| Gross Profit | CN¥118.43m |
| Other Expenses | CN¥95.90m |
| Earnings | CN¥22.53m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 28, 2024
| Earnings per share (EPS) | 0.20 |
| Gross Margin | 20.81% |
| Net Profit Margin | 3.96% |
| Debt/Equity Ratio | 81.8% |
How did 300966 perform over the long term?
See historical performance and comparison